Telaprevir, Peg-IFN-alfa-2a, and RBV in Treatment-Experienced Black/African American and Non-Black/African American Subjects With Genotype 1 Chronic Hepatitis C

This is a single-arm, open-label, multicenter study of treatment-experienced participants
with Genotype 1 CHC, who self-identified as Black/African American (Group A) or who did not
self-identify as Black/African American (Group B). Participants did not achieve a sustained
virologic response 24 weeks after at least 1 prior course of Peg-IFN-alfa-2a/RBV therapy of
standard duration, and have 1 of the following viral responses:

- Prior relapse: Participant had a documented undetectable hepatitis C virus ribonucleic
acid (HCV RNA) level at the planned end of treatment of at least 42 weeks duration (HCV
RNA evaluated anytime between 3 weeks before and 6 weeks after the last dose of Peg
IFN-alfa-2a or RBV).

- Prior null response: Participant had a <2-log10 decrease in HCV RNA at 12 weeks, during
prior Peg IFN-alfa-2a/RBV treatment, but never achieved undetectable HCV RNA while on
treatment.

- Prior partial response: Participant had a >=2-log10 decrease in HCV RNA at 12 weeks,
during prior Peg IFN-alfa-2a/RBV treatment, but never achieved undetectable HCV RNA
while on treatment.

Inclusion Criteria:

- Participants self-identify as Black/African American (Group A) or did not
self-identify as Black/African American (Group B)

- Participants have Genotype 1 CHC and laboratory evidence of hepatitis C virus (HCV)
infection for at least 6 months

- Participants did not achieve sustained viral response 24 weeks after last dose of
study drug (SVR24), after at least 1 prior course of Peg-IFN-alfa-2a/RBV therapy of
standard duration

Exclusion Criteria:

- Participants have received previous treatment with telaprevir or any other protease
inhibitor(s) for CHC

- Participants who have evidence of hepatic decompensation

- Participants have diagnosed or suspected hepatocellular carcinoma

- Participants have any other cause of significant liver disease in addition to HCV

- Participants are currently abusing illicit drugs or alcohol, or have history of
illicit substance or alcohol abuse within 2 years before the screening visit

- Participants who participated in any investigational drug study within 90 days before
dosing